Thomas J. Schall

Thomas J. Schall, listed as chief executive, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in ChemoCentryx, Inc. and Immuneering Corp. Over a trading history stretching from 1 October 2012 to 15 January 2026, the count stands at 178 filings.

In open-market terms, that means 4 purchases worth €201k on one side and 100 sales worth €51.9M on the other. Taken together, the sales exceed the purchases by €51.7M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 6 share grants and 66 option exercises. Since January 2026: 1 purchase and no sales on the market.

In size, the median ticket on the buying side is €54k. 3 out of 4 purchases came within 30 days of a purchase by at least one other insider of the same company. Purchases made close together by different insiders form what is called a cluster. Looking at 4 purchases old enough to measure, the stock rose over the following 90 days in 75% of cases; the median change was +55.3%. Past outcomes like these are no guarantee of what comes next.

Most recently, on 20 January 2026, the filings show an open-market purchase worth €87k in Immuneering Corp. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.